Nova Eye Medical Limited (EYE.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.16 (+6.67%) as of
Key statistics
- Market cap
- 45.59M
- Forward P/E
- 20.00
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.1000 – 0.2050
- Beta
- 0.93
- Revenue (TTM)
- 34.87M
- Profit margin
- -12.43%
- Analyst target
- A$0.425
- Volume
- 900.57k
About Nova Eye Medical Limited
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Kent Town, SA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.